| For: | Garbuzenko DV. Pathophysiological mechanisms of hepatic stellate cells activation in liver fibrosis . World J Clin Cases 2022; 10(12): 3662-3676 [PMID: 35647163 DOI: 10.12998/wjcc.v10.i12.3662] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v10/i12/3662.htm |
| Number | Citing Articles |
| 1 |
Wanying Tan, Jiangting Deng, Lingjun Qi, Zhenghuai Tan. The role of hepatic sinusoidal microenvironment in NASH: pathogenesis, animal models, and therapeutic prospects. Frontiers in Pharmacology 2025; 16 doi: 10.3389/fphar.2025.1467950
|
| 2 |
Mennatallah Saied, Mary Wadie, Salwa Fouad, Alyaa Farid, Mohamed Nasser. Dysregulation of the IL-6/hepcidin axis in Egyptian systemic lupus erythematosus patients: associations with anemia of inflammation and liver fibrosis. The Egyptian Journal of Internal Medicine 2026; 38(1) doi: 10.1186/s43162-026-00631-0
|
| 3 |
Anand Kumar Shah, Souvik Banerjee, Shareen Singh, Vetriselvan Subramaniyan, Thakur Gurjeet Singh. Methotrexate-induced hepatotoxicity-mechanism, clinical cases and treatment approaches. Toxicological Research 2026; doi: 10.1007/s43188-026-00345-z
|
| 4 |
Rui Tang, Jing Luo, Xiaoxia Zhu, Pengyu Miao, Hong Tang, Yue Jian, Sibei Ruan, Feng Ling, Mingxi Tang. Recent progress in the effect of ferroptosis of HSCs on the development of liver fibrosis. Frontiers in Molecular Biosciences 2023; 10 doi: 10.3389/fmolb.2023.1258870
|
| 5 |
Ahmad Ziada, Cuiyan Xin, Ahmed O. Elzoghby. Recent updates on engineered nanomedicines for treatment of fibrosis. Nanomedicine 2026; 21(6) doi: 10.1080/17435889.2026.2628236
|
| 6 |
Jianhao Jiang, Ilgiz Gareev, Tatiana Ilyasova, Alina Shumadalova, Weijie Du, Baofeng Yang. The role of lncRNA-mediated ceRNA regulatory networks in liver fibrosis. Non-coding RNA Research 2024; 9(2) doi: 10.1016/j.ncrna.2024.01.001
|
| 7 |
Alissa M. Cutrone, Heidi Yeh, Korkut Uygun, O. Berk Usta. Preclinical Models of Metabolic Dysfunction–Associated Steatotic Liver Disease for Therapeutic Testing.
Annual Review of Biomedical Engineering
2026; 28(1) doi: 10.1146/annurev-bioeng-081325-053420
|
| 8 |
Zhiwei Su, Yuxue Ding, Juan Xue, Jun Sun, Chunyan Ji. Identifying SUMOylation-related genes in liver fibrosis with bioinformatics and experimental models for diagnostic insights. Scientific Reports 2025; 15(1) doi: 10.1038/s41598-025-23516-8
|
| 9 |
Madhurani ., Pooja Negi, Digvijay Singh, Alfisha ., Sweta Kumari, Shoyab Ali. Anti-fibrotic Potential of <i>Moringa oleifera</i> in Hepatic Fibrosis: Molecular Mechanisms and Pharmacological Evidence. Journal of Natural Remedies 2026; doi: 10.18311/jnr/2026/54532
|
| 10 |
Keiya Watakabe, Masato Miyoshi, Sei Kakinuma, Ayako Sato, Jun Tsuchiya, Taro Shimizu, Tomohiro Mochida, Kento Inada, Shun Kaneko, Fukiko Kawai‐Kitahata, Miyako Murakawa, Sayuri Nitta, Mina Nakagawa, Shigeru Oshima, Mamoru Watanabe, Averil Ma, Yasuhiro Asahina, Ryuichi Okamoto. A20 in hepatic stellate cells suppresses chronic hepatitis by inhibiting DCLK1–JNK pathway‐dependent chemokines. The FASEB Journal 2024; 38(13) doi: 10.1096/fj.202400109R
|
| 11 |
Mphatso Mayuni Chaponda, Ho Yin Pekkle Lam. Schistosoma antigens: A future clinical magic bullet for autoimmune diseases?. Parasite 2024; 31 doi: 10.1051/parasite/2024067
|
| 12 |
Sangeetha P. Kademani, Krishna S. Nallagangula, Prabhudas Nelaturi. Role of long non-coding RNAs in alcoholic liver diseases. Exploration of Digestive Diseases 2026; 5 doi: 10.37349/edd.2026.1005118
|
| 13 |
Sara Mohammadi Miyanroodan, Muhammad Sohail. Recent advances in engineered exosomes for targeted microRNA delivery to reverse liver fibrosis. Journal of Drug Delivery Science and Technology 2026; 122 doi: 10.1016/j.jddst.2026.108447
|
| 14 |
Luis A. Rodríguez-Rojas, Leticia Bucio-Ortiz, Verónica Souza-Arroyo, María Concepción Gutiérrez-Ruiz, Luis E. Gómez-Quiroz, Roxana U. Miranda-Labra. Cholesterol and the gut-liver axis: unraveling their role in the onset and progression of metabolic-associated steatotic liver disease. Exploration of Digestive Diseases 2025; doi: 10.37349/edd.2025.100583
|
| 15 |
Qun Wei, Cailing Gan, Meng Sun, Yuting Xie, Hongyao Liu, Taixiong Xue, Conghui Deng, Chunheng Mo, Tinghong Ye. BRD4: an effective target for organ fibrosis. Biomarker Research 2024; 12(1) doi: 10.1186/s40364-024-00641-6
|
| 16 |
Le Thi Thanh Thuy, Hoang Hai, Pham Tuan Anh, Nguyen Bui Tam Chi, Tran Van Bao, Tran Dang Anh Huyen, Nguyen Tran Quang Sang, Michelle L. Hermiston. Therapeutic Potential of Cytoglobin and Neuroglobin in Oxidative Stress-Driven Liver Diseases. Antioxidants 2026; 15(4) doi: 10.3390/antiox15040485
|
| 17 |
Muthusethupathi Sharmila, Karthik Shree Harini, Devaraj Ezhilarasan. Modulating hepatic stellate cell senescence: A promising therapeutic strategy for liver fibrosis. Hepatobiliary & Pancreatic Diseases International 2026; doi: 10.1016/j.hbpd.2026.04.006
|
| 18 |
Mengqin Yuan, Lichao Yao, Ping Chen, Zheng Wang, Pingji Liu, Zhiyu Xiong, Xue Hu, Lanjuan Li, Yingan Jiang. Human umbilical cord mesenchymal stem cells inhibit liver fibrosis via the microRNA-148a-5p/SLIT3 axis. International Immunopharmacology 2023; 125 doi: 10.1016/j.intimp.2023.111134
|
| 19 |
Nivya Vijayan, Madan Kumar Perumal. Cholesterol Depletion Activate Hepatic Stellate Cells Mediated Through SREBP‐2 Signaling. Journal of Cellular Physiology 2025; 240(1) doi: 10.1002/jcp.31476
|
| 20 |
Nan Wu, Meiyi Song, Fan Zhang, Sayed Obaidullah Aseem, Phillip B. Hylemon, Huiping Zhou. Dysregulation of sphingolipid metabolism in liver fibrosis. Metabolism and Target Organ Damage 2024; 4(4) doi: 10.20517/mtod.2024.38
|
| 21 |
Qing-Qing Liu, Jing Chen, Tao Ma, Wei Huang, Cui-Hua Lu. DCDC2 inhibits hepatic stellate cell activation and ameliorates CCl4-induced liver fibrosis by suppressing Wnt/β-catenin signaling. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-59698-w
|
| 22 |
Enwar Abdalkarim AbdalHussin, Zariyantey Abd Hamid, Muhd Hanis Md Idris, Maizatul Hasyima Omar, Izatus Shima Taib. Bisphenol F and Steatotic Liver Disease: Resolving the PXR Paradox Through Stress Pathway Mechanisms. Biomedicines 2025; 14(1) doi: 10.3390/biomedicines14010030
|
| 23 |
Jin-Pei Liu, Shao-Hua Song, Pei-Mei Shi, Xiao-Yu Qin, Bai-Nan Zheng, Shu-Qing Liu, Chen-Hong Ding, Xin Zhang, Wei-Fen Xie, Yi-Hai Shi, Wen-Ping Xu. miR-541 is associated with the prognosis of liver cirrhosis and directly targets JAG2 to inhibit the activation of hepatic stellate cells. BMC Gastroenterology 2024; 24(1) doi: 10.1186/s12876-024-03174-2
|
| 24 |
Shahid Habib, Andrew Johnson. An overview of pathogenesis of metabolic dysfunction-associated steatotic liver disease. Exploration of Digestive Diseases 2024; doi: 10.37349/edd.2024.00061
|
| 25 |
Kashif Maroof, Ronald Fook Seng Lee, Pinar Karacabey, Rükan Genç. Peptide-Functionalized Liposomal Nanocarriers for Targeted Therapy of Liver Fibrosis and Hepatocellular Carcinoma: Design, Mechanisms, and Clinical Prospects. ACS Pharmacology & Translational Science 2026; 9(2) doi: 10.1021/acsptsci.5c00719
|
| 26 |
Wen-Jie Sun, Ming-Hui Li, Yang Yang, Qi-Qi Dong, Hui Tao, Chao Lu, Jing-Jing Yang. Novel insights on post-translational modifications of nucleic acid methylation proteins in hepatic fibrosis. Pharmacological Research 2025; 218 doi: 10.1016/j.phrs.2025.107825
|
| 27 |
Lin Wen, Xiaolian Liu, Dejun Yang, Zihao Sun, Chuipeng Liang, Jijiao Wu, Long Xie, Rong Xing, Xiaofang Li. Nanoparticle: Pathogenesis, Innovative Diagnosis, and Therapy of Liver Fibrosis. ChemistrySelect 2025; 10(7) doi: 10.1002/slct.202500446
|
| 28 |
Zhichao Jiang, Haitao Wang, Han Li, Zhiqiang Chen, Baiyu Sun. Single-cell profiling reveals lineage-specific fibroblast stromal subtypes drive ECM remodeling and immune modulation in the hepatocellular carcinoma tumor microenvironment. Medical Oncology 2026; 43(2) doi: 10.1007/s12032-025-03220-3
|
| 29 |
Giulia Chiabotto, Armina Semnani, Elena Ceccotti, Stefania Bruno. Extracellular vesicles: emerging therapeutic agents for liver fibrosis. Extracellular Vesicles and Circulating Nucleic Acids 2025; 6(2) doi: 10.20517/evcna.2025.08
|
| 30 |
Osama A. Mohammed, Mahmoud E. Youssef, Ahmed S. Doghish, Rabab S. Hamad, Mustafa Ahmed Abdel-Reheim, Mushabab Alghamdi, Mohannad Mohammad S. Alamri, Jaber Alfaifi, Masoud I.E. Adam, Muffarah Hamid Alharthi, Abdullah Hassan Alhalafi, Emad Bahashwan, Assad Ali Rezigalla, Daad Fuad BinAfif, Sameh Abdel-Ghany, Mohammed A. Attia, Elsayed A. Elmorsy, Tohada M. AL-Noshokaty, Heba Fikry, Lobna A. Saleh, Sameh Saber. A novel combination therapy targets sonic hedgehog signaling by the dual inhibition of HMG-CoA reductase and HSP90 in rats with non-alcoholic steatohepatitis. European Journal of Pharmaceutical Sciences 2024; 198 doi: 10.1016/j.ejps.2024.106792
|
| 31 |
Qiying Pei, Qian Yi, Liling Tang. Liver Fibrosis Resolution: From Molecular Mechanisms to Therapeutic Opportunities. International Journal of Molecular Sciences 2023; 24(11) doi: 10.3390/ijms24119671
|
| 32 |
Carlo Airola, Simone Varca, Angelo Del Gaudio, Fabrizio Pizzolante. The Covert Side of Ascites in Cirrhosis: Cellular and Molecular Aspects. Biomedicines 2025; 13(3) doi: 10.3390/biomedicines13030680
|
| 33 |
Linmao Ye, Jiaxin Huang, Xiaofan Liang, Wenqin Guo, Xiguang Sun, Chang Shao, Yi He, Junjie Zhang. Jiawei Taohe Chengqi Decoction attenuates CCl4 induced hepatic fibrosis by inhibiting HSCs activation via TGF-β1/CUGBP1 and IFN-γ/Smad7 pathway. Phytomedicine 2024; 133 doi: 10.1016/j.phymed.2024.155916
|
| 34 |
Bingyuan Fei, Hui Wang, Yu Ding, Nannan Shao, Panyue Wen, Yanwei Cao, Junjie Li, Masaru Tanaka, Zheng Wang, Shuo Li. Reprogramming cellular senescence of hepatic stellate cells to combat liver fibrosis by targeted nanodrugs. Materials Today Bio 2025; 33 doi: 10.1016/j.mtbio.2025.101996
|
| 35 |
Poonam Sahu, Trilochan Satapathy. Liver targeted nanomedicine for treatment of fibrosis and hepatocellular carcinoma: Emerging strategies in ligand-guided, stimuli-responsive and gene-based delivery. Journal of Drug Delivery Science and Technology 2026; 116 doi: 10.1016/j.jddst.2025.107935
|
| 36 |
Fernanda M. Martínez-Díaz, Elsie A. Jiménez-Cuevas, Mariana M. Ramírez-Mejía, Sarai Gómez-Camacho, Nahum Méndez-Sánchez. The interplay of insulin resistance, glycemic variability, and metabolic dysfunction-associated steatotic liver disease. Exploration of Digestive Diseases 2026; 5 doi: 10.37349/edd.2026.1005115
|
| 37 |
Yan Li, Yuyuan Hu, Yuan He, Yuhang Yang, Dingwen Xue, Erkui Xue, Jinghan Jia, Wei Zhang, Jinxi Wang. Loss of immunometabolic adaptability in MASH: gut-derived signals drive macrophage reprogramming and fibrosis. Frontiers in Immunology 2026; 17 doi: 10.3389/fimmu.2026.1793092
|
| 38 |
Xiaoxue Hou, Yuwen Li, Jiali Song, Linya Peng, Wen Zhang, Rui Liu, Hui Yuan, Tiantong Feng, Jieying Li, Wenting Li, Chuanlong Zhu. METTL14 reverses liver fibrosis by inhibiting NOVA2 through an m6A-YTHDF2–dependent mechanism. Hepatology Communications 2023; 7(8) doi: 10.1097/HC9.0000000000000199
|
| 39 |
Linlin Jiang, Qin Meng, Lixiu Liu, Weihang Li. A Comprehensive Review on Molecular Mechanisms, Treatments, and Brief Role of Natural Products in Hepatocellular Cancer. Natural Product Communications 2024; 19(9) doi: 10.1177/1934578X241284873
|
| 40 |
Chen Chen, Bo Huang, Mengting Hu, Shengpeng Yang, Bo Lan, Dejun Cui, Palash Mandal. Identification of Key Targets of Herbal Compounds for Liver Fibrosis Using Network Pharmacology Combined With Transcriptomics. Gastroenterology Research and Practice 2026; 2026(1) doi: 10.1155/grp/9985154
|
| 41 |
Maria Ciałowicz, Marek Woźniewski, Eugenia Murawska-Ciałowicz, Piotr Dzięgiel. The Influence of Irisin on Selected Organs—The Liver, Kidneys, and Lungs: The Role of Physical Exercise. Cells 2025; 14(16) doi: 10.3390/cells14161228
|
| 42 |
Xiao-Xue Hou, Yu-Wen Li, Jia-Li Song, Wen Zhang, Rui Liu, Hui Yuan, Tian-Tong Feng, Zheng-Yi Jiang, Wen-Ting Li, Chuan-Long Zhu. Cryptotanshinone induces apoptosis of activated hepatic stellate cells <i>via</i> modulating endoplasmic reticulum stress. World Journal of Gastroenterology 2023; 29(17): 2616-2627 doi: 10.3748/wjg.v29.i17.2616
|
| 43 |
Weijing Lai, Bo Wang, Rongshuang Huang, Chuyue Zhang, Ping Fu, Liang Ma. Ferroptosis in organ fibrosis: From mechanisms to therapeutic medicines. Journal of Translational Internal Medicine 2024; 12(1) doi: 10.2478/jtim-2023-0137
|
| 44 |
Chih-Hung Lin, Ching-Feng Cheng, Yi-Shiou Chiou, Inga Wang, Chan-Yen Kuo. Molecular Biological Mechanisms of Action of Chrysophanol in Hepatic Stellate Cells Activated by Hepatic B Virus X Based on Network Pharmacology. Intervirology 2024; 67(1) doi: 10.1159/000542355
|
| 45 |
Mohammed Sohel Meah, Pharkphoom Panichayupakaranant, Mohammed Abu Sayeed, Min Gab Kim. Isolation and Pharmacochemistry of α-Mangostin as a Chemotherapeutic Agent. Pharmacognosy Magazine 2025; 21(1) doi: 10.1177/09731296241262567
|
| 46 |
Mehmet A. KOSEKLI, Gulali AKTAS. Pathogenesis, diagnosis and management of chronic hepatitis B related liver fibrosis. Minerva Gastroenterology 2025; 71(3) doi: 10.23736/S2724-5985.25.03862-8
|
| 47 |
Vikram Nimbalkar, Neeraj Vyawhare. L‐Carnitine Protects Against Cisplatin‐Induced Activation of Human Hepatic Stellate Cells via Inflammatory Cytokines and Nitrosative Stress. Journal of Applied Toxicology 2026; 46(6) doi: 10.1002/jat.70006
|
| 48 |
Huda R. M. Rashdan, Sarah Hassan, Sara Maher, Hend Okasha. Towards novel liver injury therapies based on design, synthesis and therapeutic efficacy of novel sulfone bis-compound on liver necrosis. Scientific Reports 2025; 15(1) doi: 10.1038/s41598-025-02483-0
|
| 49 |
Jeong-Yoon Lee, Young-Min Jee, Keungmo Yang, Tom Ryu. Alcohol-Induced Oxidative Stress and Gut–Liver–Brain Crosstalk: Expanding the Paradigm from ALD to MetALD. Antioxidants 2025; 14(10) doi: 10.3390/antiox14101196
|
| 50 |
莉 田. Study on the Mechanism of Blood Circulation in Patients with Liver Fibrosis. Advances in Clinical Medicine 2022; 12(11) doi: 10.12677/ACM.2022.12111416
|
| 51 |
Fatma E. Hassan, MennaAllah M. Hassanien, Asmaa Selmy, Lamiaa Mohamed Mahmoud, Amal Darwish, Basant A. Aldreny. Beyond glycemic control: the cardiac and hepatic benefits of SGLT2 and DPP-4 inhibitors in mitigating chronic cadmium-induced inflammation, oxidative/nitrative stress, apoptosis and fibrosis. Frontiers in Physiology 2026; 16 doi: 10.3389/fphys.2025.1752370
|
| 52 |
Janitha M. Unagolla, Subarna Das, Riley Flanagan, Marin Oehler, Jyothi U. Menon. Targeting chronic liver diseases: Molecular markers, drug delivery strategies and future perspectives. International Journal of Pharmaceutics 2024; 660 doi: 10.1016/j.ijpharm.2024.124381
|
| 53 |
Wen Jia, Nannan Zhang, Daijiang Liu, Pengxiang Yu, Tao Lei, Yun He, Yang Bi. The role and mechanisms of vitamin A in suppressing hepatic stellate cell activation. Apoptosis 2026; 31(1) doi: 10.1007/s10495-025-02237-3
|
| 54 |
Ghorbanali Rahimian, Saeid Heidari-Soureshjani, Karamali Kasiri. The Biological Effects and Mechanisms of Fisetin on Hepatotoxicity, Liver Injury and Liver Fibrosis: A Systematic Review. The Natural Products Journal 2025; 15(8) doi: 10.2174/0122103155333233240906193500
|
| 55 |
Peng Ji, Yan Li, Zihan Wang, Siyu Jia, Xinyi Jiang, Hui Chen, Qun Wang. Advances in precision gene editing for liver fibrosis: From technology to therapeutic applications. Biomedicine & Pharmacotherapy 2024; 177 doi: 10.1016/j.biopha.2024.117003
|
| 56 |
Jea Il Kim, Hyae Gyeong Cheon. Melatonin ameliorates hepatic fibrosis via the melatonin receptor 2-mediated upregulation of BMAL1 and anti-oxidative enzymes. European Journal of Pharmacology 2024; 966 doi: 10.1016/j.ejphar.2024.176337
|
| 57 |
Yiheng Zhang, Mulan Xing, Fansheng Meng, Ling Zhu, Qingchuan Huang, Tianle Ma, Huihua Fang, Xujing Gu, Suzhou Huang, Xinyu Wu, Gaohong Lv, Jun Guo, Li Wu, Xin Liu, Zhipeng Chen. The mechanical mechanism of angiotensin II induced activation of hepatic stellate cells promoting portal hypertension. European Journal of Cell Biology 2024; 103(2) doi: 10.1016/j.ejcb.2024.151427
|
| 58 |
Irina Cardoso-Lezama, Erika Ramos-Tovar, Jaime Arellanes-Robledo, Eduardo E. Vargas-Pozada, Verónica Rocío Vásquez-Garzón, Saúl Villa-Treviño, Pablo Muriel. Serum α-SMA is a potential noninvasive biomarker of liver fibrosis. Toxicology Mechanisms and Methods 2024; 34(1) doi: 10.1080/15376516.2023.2244061
|
| 59 |
Gehad Nasr, Doaa Mohamed Elroby Ali, Michael A. Fawzy, Fares E.M. Ali, Moustafa Fathy. Combined quercetin with phosphodiesterase inhibitors; sildenafil and pentoxifylline alleviated CCl4-induced chronic hepatic fibrosis: Role of redox-sensitive pathways. Food and Chemical Toxicology 2025; 201 doi: 10.1016/j.fct.2025.115442
|
| 60 |
Hadis Gerami, Hassan Mozaffari-Khosravi, Asieh Mansour, Amir Ali Sohrabpour, Hossein Poustchi, Amir Pejman Hashemi Taheri, Mahmoud Reza Jaafari, Sara Jambarsang, Sayyed Saeid Khayyatzadeh. Effect of nano-curcumin supplementation on liver fibrosis in patients with NAFLD-associated fibrosis: a double-blind randomized controlled trial. Scientific Reports 2025; 15(1) doi: 10.1038/s41598-025-21862-1
|
| 61 |
Simone La Frazia, Alessia Magnapera, Lorenzo Piermatteo, Stefano D’Anna, Leonardo Duca, Valentina Svicher, Romina Salpini. Direct Viral Mechanisms Underlying the Onset of HBV-Related Hepatocellular Carcinoma and Implications for Therapeutic Strategies. Viruses 2026; 18(2) doi: 10.3390/v18020185
|
| 62 |
Rabab Abdel‐Majeed Hegazy. Unraveling Liver Cirrhosis: Bridging Pathophysiology to Innovative Therapeutics. Journal of Gastroenterology and Hepatology 2025; 40(10) doi: 10.1111/jgh.70037
|